Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Comparing individual and group intervention for psychological adjustment in people with multiple sclerosis: A feasibility randomised controlled trial.
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen.
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
Protection of tregs, suppression of Th1 and th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline.
Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis.
Multiple sclerosis: clinical features and MRI findings in Northern China.
Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors.
New EMA Advice to Reduce PML Risk With Natalizumab (Tysabri) in MS
Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study.
Parkinsonism in multiple sclerosis patients: A casual or causal association?
Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder.
Neuroscience. To learn is to myelinate.
[Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis.
Ampyra for Optic Neuritis in MS
Alemtuzumab for multiple sclerosis: who and when to treat?
The discovery of natalizumab, a potent therapeutic for multiple sclerosis.
Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran.
Bupropion-Related Visual Hallucinations in a Veteran With Posttraumatic Stress Disorder and Multiple Sclerosis.
A Simple Sign for Recognizing Off-Axis OCT Measurement Beam Placement in the Context of Multicentre Studies.
Small molecule glutaminase inhibitors block glutamate release from stimulated microglia.
The first 10 years with multiple sclerosis: The longitudinal course of daily functioning.
Suicide risk in multiple sclerosis: A systematic review of current literature.

Pages